To contact us, please fill in the form below.
PROs in the news
- 2020: TALAPRO-2: a Placebo-Controlled Phase III Study of Talazoparib (TALA) Plus Enzalutamide (ENZA) for Patients with First-Line Metastatic Castration-Resistant Prostate Cancer - UroToday
- ASCO 2020:Health-Related Quality of Life in PROfound for Olaparib vs Enzalutamide or Abiraterone in mCRPC w... - UroToday
- Coronavirus: 5 key pieces of CT data we don’t have - Middletown Press
- Oral ADT Slashes Heart Risk in Advanced Prostate Cancer - MedPage Today
- ASCO 2020: A Phase III Trial of Docetaxel versus Docetaxel and Radium-223 in Patients with mCRPC: DORA - UroToday